Investigational New Drugs **13:** 367–369, 1996.

CONTENTS VOL. 13, 1996

Preclinical Studies

Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®) – D.J. Dykes, M.C. Bissery, S.D. Harrison, Jr., W.R. Waud 1–11

P-glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine®) – D.J. Adams, V.C. Knick 13–21

Preclinical antitumor activity of ethyldeshydroxysparsomychin in combination with cisplatin – H.P. Hofs, D.J.Th. Wagener, V. De Valk-Bakker, H. Van Rennes, D. De Vos, W.H. Doesburg, H.C.J. Ottenheijm, W.J. De Grip 23–32

Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons – M.V. Marshall, K. Dee Carey, D.D. Von Hoff, J.G. Kuhn 33–36

Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes – S. Urien, P. Nguyen, G. Bastian, C. Lucas, J-P. Tillement 37–41

Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system – A-R. Hanauske, G.M. Clark, D.D. Von Hoff 43–49

Stimulation of tumor growth *in vitro* and *in vivo* by suramin on the VX2 model – L.H. Ramirez, M. Julieron, M. Bonnay, S. Koscielny, Z. Zhao, A. Gouyette, J-N. Munck 51–53

Phase I Studies

Phase I trial of pentosan polysulfate – S. Swain, B. Parker, A. Wellstein, M.E. Lippman, C. Steakley, R. DeLap 55–62

A phase I study of sulofenur in refractory pediatric malignant solid tumors – C.B. Pratt, L.C. Bowman, N. Marina, A. Pappo, L. Avery, X. Luo, W.H. Meyer 63–66

Phase II Studies

Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study – S.K. Williamson, J.J. Crowley, R.B. Livingston, T.J. Panella, J. Wendall Goodwin 67–71

Phase II study of cisplatin, 5-fluorouracil and interferon-α in recurrent carcinoma of the cervix – C. Gonzales-de Léon, S.M. Lippman, A.P. Kudelka, J.J. Kavanagh 73–76

A phase II trial of Doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma – G.K. Schwartz, E.S. Casper 77–82

A phase II trial of piroxantrone in disseminated malignant melanoma: A Southwest Oncology of Group study – J.A. Sosman, L.E. Flaherty, P.Y. Liu, W. Fletcher, J.A. Thompson, A. Hantel, V. Sondak 83–87

Experience of the treatment with Sehydrin (Hydrazine Sulfate, HS)* in the advanced cancer patients – V.A. Filov, M.L. Gershanovich, L.A. Danova, B.A. Ivin 89–97

Bioavailability Study

Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study – D.J. Stewart, L.R. Morgan Jr., S. Verma, J.A. Maroun, M. Thibault 99–107

Announcements 109

Instructions for authors 111–112

Preclinical Studies

Preclinical pharmacokinetics and antitumor activity of imexon – R.T. Dorr, J.D. Liddil, M.K. Klein, E.M. Hersh 113–116

Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units *in vitro* – H. Depenbrock, M. Wenger, R. Peter, C. Fellbaum, T. Block, J. Rastetter, A.-R. Hanauske 117–123

Activity of the morpholino anthracycline 3′-deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin MX2 against human tumor colony-forming units *in vitro* – A.A. Ebrahim El-Zayat, M.A. Izquierdo, G.M. Clark, D.D. Von Hoff 125–131

Phase I Study

Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion – L. Dirix, G. Catimel, R. Verdonk, E. De Bruijn, B. Tranchand, C. Ardiet, A. Van Oosterom 133–136

Phase II Studies

Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588) – A.Y. Chang, Z.N. Tu, J.L. Smith, P. Bonomi, T.J. Smith, P.H. Wiernik, R. Blum 137–141

Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study – M. Slavik, P.Y. Liu, E.H. Kraut, R.B. Natale, L.E. Flaherty, V.K. Sondak 143–147

A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma – N.J. Meropol, N.J. Petrelli, Y.M. Rustum, M. Rodriguez-Bigas, L.E. Blumenson, C. Frank, E. Berghorn, P.J. Creaven 149–155

Mitomycin C and menadione for the treatment of lung cancer: a phase II trial – M. Tetef, K. Margolin, C. Ahni, S. Akman, W. Chow, L. Leong, R.J. Morgan, Jr., J. Raschko, G. Somlo, J.H. Doroshow 157–162

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors – H.S. Puc, D.F. Bajorin, G.J. Bosl, A. Amsterdam, R.J. Motzer 163–165

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study – S.K. Williamson, M.K. Wolf, M.A. Eisenberger, M. O'Rourke, W. Brannon, E.D. Crawford 167–170

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center study – W.J. Gradishar, N.J. Vogelzang, L.J. Kilton, S.J. Leibach, A.W. Rademaker, S. French, A.B. Benson, III 171–174

Brief Report

Phase I trial of diaziquone (AZQ) plus GM-CSF – L.C. Hartmann, M.M. Ames, J.M. Reid, R.L. Richardson 175–176

Announcement 177

Instructions for authors 179–180

Preclinical Studies

Developing gossypol derivatives with enhanced antitumor activity – X.S. Liang, A.J. Rogers, C.L. Webber, T.J. Ormsby, M.E. Tiritan, S.A. Matlin, C.C. Benz 181–186

Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines *in vitro* – H. Depenbrock, A. Shirvani, J. Rastetter, A.-R. Hanauske 187–193

Comparative efficacy of DMP 840 against mouse and human solid tumor models – P. Lo Russo, L. Demchik, M. Dan, L. Polin, J.L. Gross, T.H. Corbett 195–203

Phase I Studies

Phase I trial of ilmofosine as a 24 hour infusion weekly – M. von Mehren, B.J. Giantonio, C. McAleer, R. Schilder, J. McPhillips, P.J. O'Dwyer 205–210

A Phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group Study – S. Baruchel, M. Bernstein, V.M. Whitehead, S. Devine, B. Bell, R. Dubowy, H. Grier, C. Kretschmar, A.-M. Langevin, T. Vietti 211–216

Phase II Studies

A phase II trial of paclitaxel (Taxol®) as first line treatment in advanced breast cancer – S.M. Swain, S.F. Honig, M.C. Tefft, L. Walton 217–222

Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology Group (ECOG) Results – A.I. Einzig, S. Lipsitz, P.H. Wiernik, A.B. Benson III 223–227

A Phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer – N.B. Haas, R.J. Schilder, S. Nash, L.M. Weiner, R.C. Catalano, R.F. Ozols, P.J. O'Dwyer 229–233

Phase II study of topotecan in metastatic hormone-refractory prostate cancer – G.R. Hudes, R. Kosierowski, R. Greenberg, H.E. Ramsey, S.C. Fox, R.F. Ozols, C.A. McAleer, B.J. Giantonio 235–240

A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma – R.S. Witte, T. Leong, M.S. Ernstoff, R.L. Krigel, M.M. Oken, J. Harris, D.C. Tormey, D.L. Trump 241–247

Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center Study – F. Rosen, E.E. Vokes, T. Lad, M. Kies, J. Wade III, L.J. Kilton,

R. Blough, S. French, M. Mullane, A.B. Benson III 249–252

A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer – M. Degardin J.P. Armand, B. Chevallier, P. Cappelaere, M.-A. Lentz, M. David, H. Roché 253–255

Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group – G. Goss, A. Muldal, R. Lohmann, M. Taylor, P. Lopez, G. Armitage, W.P. Steward 257–260

Brief Report

Cutaneous manifestations of taxol® therapy – C.J. Link Jr., G.A. Sarosy, E.C. Kohn, M.C. Christian, P. Davis, D.O. Adamo, E. Reed 261–263

Book Review

Polyfunctionality of hemopoietic regulators (edited by M.J. Murphy) – R.D. Huhn 265–267

Instructions for authors 269–270

Preclinical Studies

Influence of minor groove binders on the eukaryotic topoisomerase II cleavage reaction with 41 base pair model oligonucleotides – A. Bell, L. Kittler, G. Löber, C. Zimmer 271–284

Evaluation of 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl) hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance *in vitro* – E.C. Sha, M.C. Sha, S.H. Kaufmann 285–294

Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice – M.W. Kunkel, K.E. Hook, C.T. Howard, S. Przybranowski, B.J. Roberts, W.L. Elliott, W.R. Leopold 295–302

Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: toward therapeutic index-based drug screening – M.J. Murphy Jr., F. Fushimi, R.E. Parchment, E. Barberá-Guillem 303–314

Phase I Studies

Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-α-2a in patients with advanced malignancies – S. Wadler, H. Haynes, R. Schechner, A. Rozenblit, P.H. Wiernik 315–320

Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks – B.J. Foster, P.M. LoRusso, E. Poplin, M. Zalupski, M. Valdivieso, A. Wozniak, L. Flaherty, D.A. Kasunic, R.H. Earhart, L.H. Baker 321–326

Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane – T. Schilling, K.B. Keppler, M.E. Heim, G. Niebch, H. Dietzfelbinger, J. Rastetter, A.-R. Hanauske 327–332

Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer – S.M. Grunberg, J. Valentine, I. Zackon, P. Unger 333–336

Phase II Studies

A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a children's cancer group study – J. Russell Geyer, F.M. Balis, M.D. Krailo, R. Heideman, E. Broxson, J.K. Sato, D. Poplack, W. A. Bleyer 337–342

Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) – J. Latreille, Y. Cormier, H. Martins, G. Goss, B. Fisher, E.A. Eisenhauer 343–346

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas – R.M. Scher, R. Kosierowski, C. Lusch, R. Alexander, S. Fox, I. Redei, F. Green, B. Raskay, K. Amfoh, P.F. Engstrom, P.J. O'Dwyer 347–354

Phase II trial of ZD1694 (Tomudex ™*) in patients with advanced pancreatic cancer – R. Pazdur, N.J. Meropol, E.S. Casper, C. Fuchs, H.O. Douglass, Jr., M. Vincent, J.L. Abbruzzese 355–358

Phase II trial of edatrexate in patients with metastatic colorectal cancer – G.H. Clamon, C.E. Riggs, Jr., R. Dreicer, R.J. Hohl 359–367

Phase II trial of trimetrexate in advanced esophageal cancer: A southwest oncology group study – T.R. Fleming, T.D. Brown, S.W. Ross, J.S. Macdonald 363–366

Contents Volume 13, 1996 367–369

Author Index 371–373
Instructions for Authors 375–376